Placeholder Banner

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

October 9, 2017

Washington, D.C. (October 9, 2017) – Biotechnology Innovation Organization (BIO) Senior Executive Vice President for Public Affairs Gary Andres issued the following statement following California Governor Jerry Brown’s signing of the drug price reporting and transparency bill Senate Bill 17 into law:

“As the world’s leader in biopharmaceutical innovation, California is home to over 2,800 companies that employ a workforce of over 242,000 dedicated men and women focused on innovative solutions to improving human health and increased patient access to breakthrough medicines.

“The legislation the Governor signed into law seriously jeopardizes the future of California’s leadership in this innovative industry. Despite its intent, this law will neither provide meaningful information to patients nor lower prescription drug costs.

“By ignoring the realities of biopharmaceutical development, Senate Bill 17 will delay or prevent future biopharmaceutical innovation by driving investment toward other industry sectors that are not burdened with this type of misguided government intrusion.”

###

Discover More
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today…
The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical…
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the following statement: "Last week, Democratic leaders announced they had reached a drug pricing “deal.” We wanted to see the details before…